{"entity":{"id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-A2102, Adebrelimab and Disitamab vedotin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06417554 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 80 participants planned, started 2024-05-27 and due to reach its primary completion in 2031-12-31. Interventions recorded: SHR-A2102, SHR-A2102 ; Adebrelimab injection and SHR-A2102 + Disitamab Vedotin For Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06417554","url":"https://clinicaltrials.gov/study/NCT06417554"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a2102","adebrelimab","disitamab-vedotin"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06417554","phase":"1/2","setting":"A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06417554","source":"https://clinicaltrials.gov/study/NCT06417554","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"ed605ea8f71246d6c191ff651d508678ab09e4484177ed676524c7b2171f6e63","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-24","leadSponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-05-27","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06417554/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}